Psilocybin Efficacy With or Without Pimavanserin Pretreatment
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age21-65
SponsorJohns Hopkins University
About this trial
Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration.
The purpose of this study is to clarify the receptor-level mechanisms underlying psilocybin's effects on mood and well-being, along with the associated neurophysiologic signatures. These mechanisms will be examined using psychometric scales, autonomic and fMRI-based neurophysiologic markers, and integrated pharmacokinetic/pharmacodynamic modeling.
Eligibility criteria
Qualifiers
Adults aged 21 to 65 years old
Fluency in English
At least high school level of education
Right-handed
Disqualifiers
Non-English speakers and those with language or hearing impairments
Left-handedness (assessed by the Edinburgh Handedness Inventory)
Any lifetime history of psychedelic use, including serotonergic compounds (e.g., psilocybin, LSD, mescaline, DMT, 5-MeO-DMT) and nontraditional psychedelics (e.g., MDMA, ketamine, ibogaine)
Presence of cardiac, pulmonary, vascular, renal, hepatic, or other significant medical comorbidities
Trial design
Treatments tested in this trial
- Psilocybin
- Pimavanserin
- Inactive Placebo
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov